Skip to main content

Table 2 Response rate of epidermal growth factor receptor tyrosine kinase inhibitors according to mutation type and treatment regimen

From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

  CR PR SD PD p value
Total (n = 363) 1 (0.3) 265 (73.0) 72 (19.8) 25 (6.9) <  0.001
EGFR mutation types
 E19del (n = 175) 1 (0.6) 132 (75.4) 33 (18.9) 9 (5.1)  
 L858R (n = 154) 0 117 (76.0) 30 (19.5) 7 (4.5)  
 Uncommon (n = 34) 0 16 (47.1) 9 (26.5) 9 (26.5)  
EGFR TKIs      0.914
 Afatinib (n = 102) 0 74 (72.5) 21 (20.6) 7 (6.9)  
 Erlotinib (n = 139) 1 (0.7) 100 (71.9) 29 (20.9) 9 (6.5)  
 Gefitinib (n = 122) 0 91 (74.6) 22 (18.0) 9 (7.4)  
  1. Data are shown as n (%) per each group
  2. CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations, EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors
\